Assessment of recovery time for the collagen products Dermicol-P35 27G and 30G - 24/04/13
Reprint requests: Nowell J. Solish, MD, FRCP, Division of Dermatology, University of Toronto, Women’s College Hospital, 76 Grenville St, Toronto, ON M5S 1B2, Canada.Abstract |
Background |
Dermicol-P35 27G and 30G are purified advanced collagen dermal fillers that are effective and well tolerated for cosmetic procedures.
Objective |
The primary objectives of this study were to: (1) document recovery time and return to daily activities after treatment with Dermicol-P35 27G, 30G, or both; and (2) assess the immediate adverse effects of these products and monitor their time to resolution.
Methods |
In all, 30 patients were treated with Dermicol-P35 27G, 30G, or both in nasolabial folds, lips, corners of the mouth, vermillion border, marionette lines, or a combination of these and monitored for 7 days. Comfort with resuming daily routine, adverse events, and satisfaction with results were documented by patients in diaries. The clinician assessed aesthetic improvement and rated satisfaction with results.
Results |
The majority of patients (63.4%) were very comfortable or comfortable returning to their daily routine immediately postprocedure. Most patients (86.7%) participated in normal work or social events within 2 days of treatment. Adverse events were mild to moderate and were resolved or tolerable by day 7. The clinician assessed that most patients had between 50% and 100% improvement over baseline for all procedures at all time points. Clinician and patients were very satisfied or satisfied with aesthetic results at days 2 and 7 postprocedure.
Limitations |
The limitations of this study were the small number of patients, the assessment of short-term results, and the lack of touch-up injections.
Conclusions |
Treatment with Dermicol-P35 27G, 30G, or both allowed for rapid return to daily activities and produced only transient and tolerable adverse events.
Le texte complet de cet article est disponible en PDF.Key words : collagen, dermal filler, Dermicol-P35 27G, Dermicol-P35 30G, recovery time
Abbreviations used : HA, MFWS, NASHA, NLF
Plan
| Supported by ColBar LifeScience Ltd. The author acknowledges that writing and editorial assistance in the preparation of this manuscript was provided by Joanna Bloom, PhD, Envision Scientific Solutions, and funded by Ortho Dermatologics Inc. |
|
| Disclosure: Dr Solish has received honoraria for presentations from Johnson and Johnson, Medicis, and Allergan, and has been a consultant for Medicis. |
Vol 62 - N° 5
P. 824-830 - mai 2010 Retour au numéro
Article précédent
- Four novel ATP2A2 mutations in Slovenian patients with Darier disease
- Aleksandar Godic, Branka Korošec, Jovan Miljković, Aleksej Kansky, Damjan Glavač
- Clinical and pathologic characteristics of disseminated cutaneous coccidioidomycosis
- John B. Carpenter, Jacob S. Feldman, William H. Leyva, David J. DiCaudo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?